ECS: Spectroscopic Assessment of Intramyocardial Oxygen Saturation During Open-Heart Surgery

Sponsor
Spectrocor (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06084091
Collaborator
(none)
40
1
25.8
1.5

Study Details

Study Description

Brief Summary

The goal of this observational study is to test in the safety and performance of intraoperative myocardial spectroscopic measurement in open-heart surgery patients

The main questions it aims to answer are:
  • The Devices can record myocardial spectrometric data for analysis, and

  • How these measures correlate with the occurring events, procedures, and clinical parameters during the operation.

  • Number of participants with device-related adverse events as assessed by CTCAE v4.0

Condition or Disease Intervention/Treatment Phase
  • Device: Myocardial spectrometric measurement

Detailed Description

The study design is based on measuring the depth of ischemia during the operation, which is compared to the intraoperative and postoperative morbidity of the patient, especially to the dysfunction of the heart. A qualified and experienced Monitor is assigned for the study to oversee and document the progress of the trial. The Monitor ensures the trial performance in accordance with the Protocol and Good Clinical Practice (GCP). The trial team conforms to ISO 13485 quality standards and ISO 14155 GCP. Processes included in the monitoring activities are documented in the quality management system. Below are described the summaries of all these activities. Source data will be collected and transferred into the electronic CRFs by site staff, and the collected data quality and the conformity to the Good Clinical Practice will be assessed by monitoring. Based on a risk assessment performed, a Data Monitoring Committee shall not be established. Clinical Research Associate (CRA) is responsible for checking the accuracy and completeness of Case Report Form (CRF) entries, source documents, and other investigation-related records against each other. Other responsibilities of CRA, including detailed Source Data Verification (SDV), are documented by the clinical project manager (CPM) or head of clinical research (HCR)(both are sponsor's representatives). SDVs will be performed and documented during monitoring visits. Monitoring planning, reporting, and visits are pre-defined and documented with pre-made templates per the sponsor's quality management system. Monitoring visits will be performed to cover data from all study participants, and according to QMS and the Standard Operation Procedures. The monitoring shall ensure that all source documentation is precise and document control is exercised in all relevant documentation. The monitoring ensures, that the Adverse events are always reported and appropriate authorities or stakeholders are informed.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Spectroscopic Assessment of Intramyocardial Oxygen Saturation During Open-Heart Surgery
Anticipated Study Start Date :
Oct 6, 2023
Anticipated Primary Completion Date :
Nov 30, 2025
Anticipated Study Completion Date :
Nov 30, 2025

Outcome Measures

Primary Outcome Measures

  1. Myocardial spectrometric recording [During operation]

    Can the device record myocardial spectrometric data during open-heart surgery

  2. Measurement correlation [During operation]

    How the measurements correlate with the occurring events, procedures, and clinical parameters during the operation.

Secondary Outcome Measures

  1. Adverse event assessment [From admission to discharge, up to 2 weeks]

    Assessment of the adverse events of the device.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Any 18 to 90-year-old patient scheduled for an open-heart operation

  • The ability to understand the study's objective and the risks involved.

  • Informed consent obtained, including the agreement to authorization to use the protected personal patient records according to privacy legislation.

Exclusion Criteria:
  • Inability to obtain an informed consent form

  • Patients included as vulnerable population according to Finnish Medical Research Act, including retarded, pregnant women, nursing mothers, prisoners, or forensic patients.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Heart and Lung Center Helsinki Uusimaa Finland 00029

Sponsors and Collaborators

  • Spectrocor

Investigators

  • Principal Investigator: Peter Raivio, PhD, Chief of Department, Head and Lung Center, Hospital District of Helsinki and Uusimaa

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Spectrocor
ClinicalTrials.gov Identifier:
NCT06084091
Other Study ID Numbers:
  • Safe-op 1.0 ECS
First Posted:
Oct 16, 2023
Last Update Posted:
Oct 16, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Spectrocor
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 16, 2023